Sanford, Maine, July 22nd, 2020 - NESA, The Baker Company’s consultative sales group, is proud to announce our new partnership with Allentown, LLC.
GSK have stated that they will invest a 10% stake in CureVac. The hope behind the collaboration is to develop up to five mRNA-based vaccines with the technology already being used by the biotech company. Discover more.
From common modifications on user controls and work surfaces to more complex designs for ergonomic, microscope ready view screens and in wall monitors, we will work with you to meet the unique requirements of your lab. Find out more.
Johnson & Johnson plan to begin a late-stage human trial in September, ahead of schedule. Initially starting in The Netherlands, Spain and Germany this week, the trial will then begin in the USA. The company’s aim is to be producing 1 billion doses by the end of 2021. Read more.
Baker thrives on helping scientists and researchers across the globe achieve their mission in almost every kind of endeavour and a wide variety of industries, including biotech, pharmacy, government, clinical and medical education research.
Wednesday 15th July, 1:00pm - 2:00pm EDT
Presented by Walker Inman, Ph.D. and Krista Rantanen, Ph.D. Dr. Inman is the co-founder and CEO of Lucid Scientific, the developer of the RESIPHER real-time metabolic analysis platform and Dr. Krista is a Physoxia ambassador, hypoxia enthusiast and cancer researcher. Director of Scientific Applications, Baker Ruskinn.
A Baker partner, BDandCo has announced the launch of their new portable, rapid antigen test. The test is able to detect the SARS-CoV-2 antigen within 15 minutes. The company will begin shipping the tests this week. Find out more for yourself.
Vaxart’s room temperature stable tablet vaccine has been selected for a non-human primate challenge study (NHP). The purpose of the study is to commit to the delivery of 300 million vaccine doses by 2021. Find out more.
Sign up to our monthly newsletter to stay up to date on everything that’s going on at Baker.